|Day Low/High||45.78 / 47.06|
|52 Wk Low/High||42.48 / 63.69|
Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement in response to a letter from Starboard Value ("Starboard"): Bristol-Myers Squibb welcomes the opinions of all of its stockholders and will review Starboard's letter and respond...
Celgene shares traded sharply lower Thursday after one of Bristol-Myers Squibb's key investors said it $74 billion takeover bid for the cancer drug specialist was too risky and expensive.
Believes the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has filed definitive proxy materials with the U.
Bristol-Myers Squibb Company (NYSE:BMY) today provided an update on its proposed acquisition of Celgene Corporation (NASDAQ:CELG).
Merck shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration.
Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bristol-Myers Squibb Company (NYSE: BMY) today announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive...
Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019, in New York.
Right now it feels as though everyone sees the obvious resistance and overbought situation.
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Stocks rose Monday amid another rush of earnings reports this week including Alphabet results due after the bell.
Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.
Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.
Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.
Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.
News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.
Jim Cramer makes sense of this market action and has your game plan for next week.
Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.
Management commentary from CAT is key on Monday.
Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.
Stocks ended mixed as global investors remain in defensive positions amid ongoing concerns over the strength of the world economy and the fate of U.S.-China trade talks.
Replacing fear with pragmatism, that is our goal.
U.S. equity futures edged higher Thursday, helped in part by stronger-than-expected semiconductor earnings, even as global investors remained defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.
U.S. stock futures rise modestly as investors retreat largely to defensive positions amid ongoing concerns over the strength of the world economy; Ford swings to a loss because of overseas weakness; Intel, Starbucks and Western Digital report earnings Thursday; Microsoft's Bing search engine is blocked in China.
These themes are working despite the turmoil in Washington and slowing global growth.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that its fourth quarter 2018 earnings call has been rescheduled for two hours earlier than previously announced.
Global stocks stalled Thursday, with investors largely retreating to defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.